top of page

RAPT Therapeutics CEO Brian Wong walks us through the company's focus on inflammatory conditions, including a lead clinical program targeting IgE, and a next-generation CCR4 in preclinical development

  • Sep 9, 2025
  • 1 min read

He describes the lead program, RPT-904, which is designed to have a longer half-life and to be more selective than omalizumab. Plus, the science behind CCR4 antagonism and how RAPT is taking learnings from an ealier program into a next-generation one.





Coverage brought to you by:


Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter

@BiotechTV

  • LinkedIn

BiotechTV

  • Facebook

BiotechTVHQ

  • TikTok

@BiotechTV

  • Instagram

@BiotechTVHQ

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

HSBC_IB_Stacked_logo.png

HSBC Innovation Banking's dedicated sector experts possess in-depth knowledge of the technology, life science and healthcare economies. With access to an extensive global network, we can help you fuel growth through venture capital and corporate investors, industry influencers, customers, and global opportunities.

​

​Through our interconnected innovation hubs in the US, UK, Israel and Hong Kong, our experts are supporting the world’s innovation economy – both clients and their investors to help them meet their growth goals.

Learn more

bottom of page